lol646 download play store
TikTok is challenging the federal government’s order to shut down its operations in Canada. The company filed in documents in Federal Court in Vancouver on Thursday. The government ordered the dissolution of TikTok’s Canadian business in November after a national security review of the Chinese company behind the social media platform. That means TikTok must "wind down" its operations in Canada, though the app will continue to be available to Canadians. TikTok wants the court to overturn the government’s order and to place a pause on the order while the court hears the case. It is claiming the minister's decision was "unreasonable" and "driven by improper purposes." The review was carried out through the Investment Canada Act, which allows the government to investigate any foreign investment with potential to harm national security. Industry Minister François-Philippe Champagne said in a statement at the time the government was taking action to address "specific national security risks," though it didn’t specify what those risks were. TikTok’s filing says Champagne "failed to engage with TikTok Canada on the purported substance of the concerns that led to the (order.)" The company argues the government ordered "measures that bear no rational connection to the national security risks it identifies." It says the reasons for the order "are unintelligible, fail to reveal a rational chain of analysis and are rife with logical fallacies." The company's law firm, Osler Hoskin & Harcourt LLP, declined to comment, while Champagne’s office did not immediately respond to a request for comment. A TikTok spokesperson said in a statement that the order would "eliminate the jobs and livelihoods of our hundreds of dedicated local employees — who support the community of more than 14 million monthly Canadian users on TikTok, including businesses, advertisers, creators and initiatives developed especially for Canada." This report by The Canadian Press was first published Dec. 10, 2024. Darryl Greer and Anja Karadeglija, The Canadian Press
Sengkang MP Jamus Lim shares his Boeuf Bourguignon recipeA Psychologist Explains Why You Should Strive For ‘Imperfect Love’
History has shown that the destinies of exiled leaders are often marked by legal challenges, political pressure, and lingering controversies. While seeking refuge abroad may offer temporary respite from immediate threats, it does not absolve former leaders of their actions or responsibilities. The fate of Assad and other exiled leaders remains uncertain, and only time will reveal the true extent of their legacies and repercussions.
European markets opened higher on Tuesday, in a shortened trading session for Christmas Eve. At the opening bell, the pan-European Stoxx 600 was up by around 0.3%, with all sectors in positive territory. Tech stocks were among those leading the gains, following a strong trading session on Monday for U.S.-listed technology shares. > 24/7 San Diego news stream: Watch NBC 7 free wherever you are Stocks in Europe ended Monday's session slightly higher, as investors reacted to more disappointing economic news out of the U.K., and the Stoxx 600 was lifted by a recovery in the share price of pharmaceuticals giant Novo Nordisk. Novo Nordisk resumed its rally on Tuesday, rising to the top of the Stoxx 600 during early deals and adding 5.7% by 8:09 a.m. London time. Shares of the Danish pharmaceuticals giant were recovering from last week's major sell-off , which followed disappointing results from the trial of its CagriSema weight loss drug. There is no economic data expected out of Europe on Tuesday. Overnight in Asia , stocks were in mixed territory as investors monitored the monetary policy outlook in Japan , the blockbuster merger between autos giants Honda and Nissan and faltering consumer confidence in South Korea . Trading is expected to be muted across the globe this week as multiple markets close early onTuesday and will remain shuttered on Wednesday for Christmas Day. Also on CNBC Holiday-thinned markets cheered by strong Wall Street finish Britain's economy flatlined in the third quarter, revised figures show Inflation and dot plotsTikTok is challenging the federal government’s order to shut down its operations in Canada. The company filed in documents in Federal Court in Vancouver on Thursday. The government ordered the dissolution of TikTok’s Canadian business in November after a national security review of the Chinese company behind the social media platform. That means TikTok must “wind down” its operations in Canada, though the app will continue to be available to Canadians. TikTok wants the court to overturn the government’s order and to place a pause on the order while the court hears the case. It is claiming the minister’s decision was “unreasonable” and “driven by improper purposes.” The review was carried out through the Investment Canada Act, which allows the government to investigate any foreign investment with potential to harm national security. Industry Minister François-Philippe Champagne said in a statement at the time the government was taking action to address “specific national security risks,” though it didn’t specify what those risks were. TikTok’s filing says Champagne “failed to engage with TikTok Canada on the purported substance of the concerns that led to the (order.)” The company argues the government ordered “measures that bear no rational connection to the national security risks it identifies.” It says the reasons for the order “are unintelligible, fail to reveal a rational chain of analysis and are rife with logical fallacies.” The company’s law firm, Osler Hoskin & Harcourt LLP, declined to comment, while Champagne’s office did not immediately respond to a request for comment. A TikTok spokesperson said in a statement that the order would “eliminate the jobs and livelihoods of our hundreds of dedicated local employees — who support the community of more than 14 million monthly Canadian users on TikTok, including businesses, advertisers, creators and initiatives developed especially for Canada.” This report by The Canadian Press was first published Dec. 10, 2024. Darryl Greer and Anja Karadeglija, The Canadian Press
Racing was abandoned in the Track Champions League at Lee Valley VeloPark in London after British Olympic champion Katy Marchant and another rider crashed over the barriers into the crowd. Marchant and German rider Alessa-Catriona Propster left the track at speed along with their bikes and collided with spectators. British Cycling said the two riders and four supporters were treated by event medics and Marchant was taken to hospital. In a statement, British Cycling added: "WBD Sports, British Cycling, Lee Valley VeloPark, and the Union Cycliste Internationale unanimously decided to suspend all further racing for the evening and want to extend their best wishes for a speedy recovery to both riders and all affected spectators. "We are working closely with all parties to review the incident before taking appropriate action." At the same venue at the 2022 Commonwealth Games a high-speed collision involving several riders resulted in England's Matt Walls being catapulted over the barriers into the crowd with his bike. The London venue installed a 1.4-metre barrier, costing £250,000, around the track this year. Thirty-one-year-old Marchant, who won Team Sprint gold at the 2024 Paris Olympics, was competing in the second heat of the women's keirin.
11. N'Golo Kante (Chelsea)In a significant show of military force, the United States carried out a series of precision airstrikes on 75 targets inside Syria in an effort to weaken the grip of the Islamic State (IS) forces in the region. The airstrikes, carried out both by manned aircraft and drones, were part of a concerted effort to degrade and dismantle the terrorist group's infrastructure and capabilities.
The Medicine Valley, once a symbol of hope and healing, now finds itself at a crossroads. The road ahead is uncertain, but one thing remains clear – the need for swift and decisive action to mitigate the impact of this devastating health crisis.In conclusion, the announcement of the Xiaomi YU7 has generated significant buzz and anticipation within the automotive industry. However, the revelation of the preemptive registration of related trademarks by third parties highlights the complexities and risks associated with brand management in the competitive electric vehicle market. As Xiaomi continues to pursue its vision of innovation and sustainability in the automotive sector, addressing trademark challenges like those surrounding the YU7 will be crucial for maintaining its competitive edge and ensuring the success of its new car model.BANGKOK — Japanese automakers Honda and Nissan will attempt to merge and create the world's third-largest automaker by sales as the industry undergoes dramatic changes in its transition away from fossil fuels. The two companies said they had signed a memorandum of understanding on Monday and that smaller Nissan alliance member Mitsubishi Motors also had agreed to join the talks on integrating their businesses. Honda will initially lead the new management, retaining the principles and brands of each company. Following is a quick look at what a combined Honda and Nissan would mean for the companies, and for the auto industry. The ascent of Chinese automakers is rattling the industry at a time when manufacturers are struggling to shift from fossil fuel-driven vehicles to electrics. Relatively inexpensive EVs from China's BYD, Great Wall and Nio are eating into the market shares of U.S. and Japanese car companies in China and elsewhere. Japanese automakers have lagged behind big rivals in EVs and are now trying to cut costs and make up for lost time. Nissan, Honda and Mitsubishi announced in August that they will share components for electric vehicles like batteries and jointly research software for autonomous driving to adapt better to dramatic changes in the auto industry centered around electrification. A preliminary agreement between Honda, Japan's second-largest automaker, and Nissan, third largest, was announced in March. A merger could result in a behemoth worth about $55 billion based on the market capitalization of all three automakers. Joining forces would help the smaller Japanese automakers add scale to compete with Japan's market leader Toyota Motor Corp. and with Germany's Volkswagen AG. Toyota itself has technology partnerships with Japan's Mazda Motor Corp. and Subaru Corp. Nissan Chief Executive Makoto Uchida, left, Honda Chief Executive Toshihiro Mibe, center, and Takao Kato, CEO of Mitsubishi Motors, right, pose for photographers during a joint news conference in Tokyo, Japan, Monday, Dec. 23, 2024. (AP Photo/Eugene Hoshiko) Eugene Hoshiko Nissan has truck-based body-on-frame large SUVs such as the Armada and Infiniti QX80 that Honda doesn't have, with large towing capacities and good off-road performance, said Sam Fiorani, vice president of AutoForecast Solutions. Nissan also has years of experience building batteries and electric vehicles, and gas-electric hybird powertrains that could help Honda in developing its own EVs and next generation of hybrids, he said. Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | SoundStack | All Of Our Podcasts "Nissan does have some product segments where Honda doesn't currently play," that a merger or partnership could help, said Sam Abuelsamid, a Detroit-area automotive industry analsyt. While Nissan's electric Leaf and Ariya haven't sold well in the U.S., they're solid vehicles, Fiorani said. "They haven't been resting on their laurels, and they have been developing this technology," he said. "They have new products coming that could provide a good platform for Honda for its next generation." Nissan said last month that it was slashing 9,000 jobs, or about 6% of its global work force, and reducing global production capacity by 20% after reporting a quarterly loss of 9.3 billion yen ($61 million). Earlier this month it reshuffled its management and its chief executive, Makoto Uchida, took a 50% pay cut to take responsibility for the financial woes, saying Nissan needed to become more efficient and respond better to market tastes, rising costs and other global changes. Fitch Ratings recently downgraded Nissan's credit outlook to "negative," citing worsening profitability, partly due to price cuts in the North American market. But it noted that it has a strong financial structure and solid cash reserves that amounted to 1.44 trillion yen ($9.4 billion). Nissan's share price has fallen to the point where it is considered something of a bargain. A report in the Japanese financial magazine Diamond said talks with Honda gained urgency after the Taiwan maker of iPhones Hon Hai Precision Industry Co., better known as Foxconn, began exploring a possible acquisition of Nissan as part of its push into the EV sector. The company has struggled for years following a scandal that began with the arrest of its former chairman Carlos Ghosn in late 2018 on charges of fraud and misuse of company assets, allegations that he denies. He eventually was released on bail and fled to Lebanon. Honda reported its profits slipped nearly 20% in the first half of the April-March fiscal year from a year earlier, as sales suffered in China. Toyota made 11.5 million vehicles in 2023, while Honda rolled out 4 million and Nissan produced 3.4 million. Mitsubishi Motors made just over 1 million. Even after a merger Toyota would remain the leading Japanese automaker. All the global automakers are facing potential shocks if President-elect Donald Trump follows through on threats to raise or impose tariffs on imports of foreign products, even from allies like Japan and neighboring countries like Canada and Mexico. Nissan is among the major car companies that have adjusted their supply chains to include vehicles assembled in Mexico. Meanwhile, analysts say there is an "affordability shift" taking place across the industry, led by people who feel they cannot afford to pay nearly $50,000 for a new vehicle. In American, a vital market for companies like Nissan, Honda and Toyota, that's forcing automakers to consider lower pricing, which will eat further into industry profits. ____ AP Auto Writer Tom Krisher contributed to this report from Detroit. Airbags, advanced driver assistance features, and high-strength materials mean that the safest cars today are far better at protecting people from injuries than ever before. Although most new cars compare well to their predecessors, some stand above the rest. The safest cars for 2025 offer excellent occupant protection and also do a good job of preventing accidents from happening in the first place. Based on testing data from the Insurance Institute for Highway Safety , or IIHS, and the National Highway Traffic Safety Administration , or NHTSA, these are some of the safest cars available today. Ranging from inexpensive compact cars and mainstream midsize sedans to stylish station wagons, posh luxury cars, and sporty coupes and convertibles, Edmunds shares a list that has something for just about everyone. For those who prefer a higher seating position and maybe some added practicality, Edmunds' list of safest SUVs is for you. Toyota 2025 Mazda 3 The stylish Mazda 3 has a lot to offer compact-car shoppers, including great looks, a composed driving experience, and reasonable fuel economy from its base 2.0-liter engine. It's also one of the safest cars in its class, earning a perfect five stars in NHTSA crash testing and sterling crashworthiness and collision avoidance scores from the IIHS. Its standard features are forward collision warning, automatic emergency braking, and lane departure prevention. Base price: $25,135 NHTSA rating: five stars IIHS rating: Top Safety Pick+ Edmunds Rating: 7.6 (out of 10) 2025 Honda Civic With mature styling, a premium interior, and an efficient hybrid powertrain option, the 2025 Honda Civic is a great option if safety is a concern since it aces almost all of the IIHS' crash tests and earns a five-star safety rating from the federal government. It also comes standard with adaptive cruise control, lane departure prevention, and forward collision warning with automatic emergency braking. The Civic falls short slightly in the IIHS' updated moderate overlap front test, which now accounts for rear passenger safety, but even so, it's one of the safest cars in its class. Base price: $25,345 NHTSA rating: five stars IIHS rating: Top Safety Pick+ Edmunds Rating: 8.2 (out of 10) 2025 Mini Cooper Reflective of parent company BMW, today's Mini Cooper is well constructed and features premium safety features that belie its small size, including automatic emergency braking and forward collision warning. Although the Mini hasn't been tested by NHTSA, the IIHS gives the Cooper its highest score of Good in the original driver-side small overlap front, moderate overlap front, and side-impact tests. That said, the IIHS doesn't place the Cooper on its Top Safety Pick or Top Safety Pick+ lists since it hasn't been evaluated on the updated battery of passenger-side small overlap front, moderate overlap front, or side-impact tests. Expect the new-for-2025 Mini Cooper to earn decent crash ratings in those scenarios, especially since it shares its strong platform with the outgoing model. Base price: $33,195 NHTSA rating: not tested IIHS rating: not rated Edmunds Rating: 7.5 (out of 10) 2025 Toyota Prius With its recent redesign, the Toyota Prius transformed from a frumpy little caterpillar to a stylish and efficient butterfly. It also became a very safe hybrid hatchback. Perfect scores in all of its government and IIHS crash tests, as well as a sophisticated system of collision avoidance technology, earn it top marks. It's also one of our favorite cars on the market, period, as evidenced by its status as a 2024 Edmunds Top Rated vehicle. Base price (2024): $29,045 NHTSA rating: five stars IIHS rating: Top Safety Pick+ Edmunds Rating: 8.0 (out of 10) Honda 2025 Honda Accord The Honda Accord is among the safest midsize sedans on the market today thanks to excellent crashworthiness scores and a competent standard collision prevention system. It's a Top Safety Pick+, beating out rivals like the Hyundai Sonata, Kia K5, and Subaru Legacy, and the Accord also earns a perfect five-star rating from NHTSA. Honda's hybrid-intensive product planning is on full display here—all but the two lowest Accord trims have a hybrid powertrain—and it's also among the most spacious cars in its class. Base price: $29,390 NHTSA rating: five stars IIHS rating: Top Safety Pick+ Edmunds Rating: 8.0 (out of 10) 2025 Toyota Camry Like its Honda Accord rival, the Toyota Camry is also an IIHS Top Safety Pick+ with a five-star NHTSA rating. It also has a very impressive suite of driver assistance and safety technology, including lane departure prevention with active centering, full-speed adaptive cruise control, and automatic emergency braking. The Camry edges out the Accord in IIHS testing thanks to a more effective collision avoidance system, but both cars are remarkably well matched otherwise. Base price: $29,495 NHTSA rating: five stars IIHS rating: Top Safety Pick+ Edmunds Rating: 8.1 (out of 10) 2025 Hyundai Ioniq 6 The fully electric Hyundai Ioniq 6 offers excellent safety and collision prevention, with excellent scores across the entire line of IIHS tests. The Ioniq 6 hasn't been tested for rollover resistance by NHTSA, but it earned a four-star front safety rating and a five-star side-impact rating in government tests. Like most EVs, the Hyundai Ioniq 6 comes standard with forward collision warning, automatic emergency braking, and lane departure prevention. It also offers up to 342 miles of all-electric driving in its longest-range trim level. Base price: $38,900 NHTSA rating: not rated IIHS rating: Top Safety Pick+ Edmunds Rating: 8.1 (out of 10) Hyundai 2025 Acura Integra The Acura Integra is a close mechanical cousin to the Honda Civic, so it's no surprise it does well in both the IIHS' and NHTSA's crash tests. The luxury hatchback is a Top Safety Pick+ and earns a perfect five stars in government testing. The AcuraWatch safety suite is standard on the Integra, bringing automatic emergency braking, lane centering, lane departure prevention, and adaptive cruise control. Base price: $34,195 NHTSA rating: five stars IIHS rating: Top Safety Pick+ Edmunds Rating: 7.4 (out of 10) 2025 Mercedes-Benz C-Class The Mercedes-Benz C-Class is a safe option in the popular small luxury sedan segment thanks to its good scores in IIHS crash testing. Mercedes' best-selling sedan also comes standard with automatic emergency braking and forward collision warning, which helps it earn a Top Safety Pick award. However, it hasn't been tested by the NHTSA. Base price: $49,600 NHTSA rating: not rated IIHS rating: Top Safety Pick Edmunds Rating: 7.9 (out of 10) 2025 Genesis G80 Both the Genesis G80 and the fully electric Genesis Electrified G80 earn a Top Safety Pick+ score from the IIHS thanks to their good scores on the agency's crash tests, as well as a comprehensive suite of active safety features that avoided collisions with simulated pedestrians. The internal-combustion-engine G80 earned a perfect five-star safety rating from NHTSA, and although the Electrified G80 hasn't been tested by the feds just yet, it should likely excel in those tests too. Base price: $58,350 NHTSA rating: five stars IIHS rating: Top Safety Pick+ Edmunds Rating: 8.0 (out of 10) 2025 Genesis G90 The flagship Genesis G90 sedan competes with the Mercedes-Benz S-Class and BMW 7 Series, and the South Korean automaker clearly hasn't skimped on safety in its fight against the establishment. Although it hasn't been subjected to the NHTSA array of tests, it aced almost all of its IIHS tests, and a long list of standard active safety and driver assistance features sets it apart from the stingy German makes that charge extra for them. Base price: $90,450 NHTSA rating: not rated IIHS rating: Top Safety Pick+ Edmunds Rating: 8.1 (out of 10) Genesis
Jim Harbaugh and Chargers focused on accomplishing more after wrapping up playoff berth
GB's Marchant crashes into London velodrome crowdMissing McCahons, Webb’s Slim Aarons refunds, the aftermath of James Wallace’s sex convictions and more unmissable arts reads
In a surprising turn of events, the coaching staff of Real Madrid has identified defender Jules Koundé as the team's most proficient shooter. Despite traditionally being known for his defensive prowess, Koundé has been making waves with his striking ability in training sessions, impressing the coaching staff and his teammates alike.TikTok files legal challenge of federal government’s shutdown order
NoneOne of the key benefits of Public Rental Housing in Fengtai District is its affordability. Designed to provide housing options for lower and middle-income residents, the rent for public rental units is significantly lower than that of market-rate apartments in the area. This means that you can enjoy high-quality accommodation without breaking the bank, allowing you to save money for other essentials or indulge in leisure activities.
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenThis report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here . Mega automobile merger Nissan and Honda have begun official merger discussions , the two companies announced on Monday. Negotiations will end June 2025. Japan-listed Honda shares were last up 13.4% on Tuesday and on track for their best day since October 2008 , after the company announced plans to buy back 24% of its issued shares by Dec. 23 next year. Taiwan tops Asian markets As of Dec. 23, Taiwan's Taiex had gained 28.85%, making it the best-performing stock market in Asia-Pacific in 2024. The Taiex's focus on tech and tech-related stocks helped supercharge its performance. Taiwan Semiconductor Manufacturing Company soared 82.12% in 2024, and Foxconn — which trades as Hon Hai Precision Industry — advanced 77.51%. Positive start to holidays U.S. markets rose on Monday on the back of a strong showing by large tech stocks. The New York Stock Exchange closes early Tuesday for Christmas Eve. Asia-Pacific stocks traded mixed on Tuesday . Japan's Nikkei 225 slipped roughly 0.4% even as Honda shares popped. Meanwhile, Hong Kong's Hang Seng index climbed more than 1%. UK GDP not OK The U.K. economy failed to expand in the three months ending September, according to revised figure from the Office for National Statistics, published Monday. Previous estimates had pegged third-quarter gross domestic product at 0.1%. Earlier this month, data from the ONS showed the U.K. economy had unexpectedly contracted by 0.1% in October. [PRO] Buffett's biggest war chest Warren Buffett's Berkshire Hathaway is currently holding $325 billion in cash — the largest amount it's hoarded in absolute terms. Cash now comprises around 30% of Berkshire's total assets, the highest proportion in 34 years, according to data from Oppenheimer. Buffett sold large quantities of Apple and Bank of America shares this year. Why is the 94-year-old legendary investor holding on to so much cash? Analysts weigh in. U.S. markets began the trading week in holiday cheer. The S&P 500 gained 0.73% and the Dow Jones Industrial Average , recovering from earlier losses, ticked up 0.16%. The Nasdaq Composite added 0.98% on the back of strong performances from large tech firms such as Nvidia , Tesla and Meta Platforms . However, shares of bitcoin proxy MicroStrategy slumped 8.8% on its first day in the Nasdaq-100 index, following the cryptocurrency's price falling to below $93,000 on Monday. That said, MicroStrategy is still among the best-performing U.S. tech companies valued at $5 billion or more, according to FactSet data. Its shares have rocketed 426% so far this year, mostly thanks to the company's stockpile of bitcoins , which it started to amass in 2020. With the rally in bitcoin following Donald Trump's election victory, MicroStrategy's bitcoin holding is now worth around $42 billion. It's the basis for the company's market capitalization ballooning to $82 billion from roughly $1.1 billion from the time it began buying bitcoin in bulk. Investors looking to ride on MicroStrategy's explosive rise should remember that the company's share price is currently trading on the back of bitcoin prices. The flipside of it is that if bitcoin prices crater for any reason — volatile as cryptocurrency can be — MicroStrategy shares may stumble too. Trading is likely to be thin this week. Markets in the U.S. will close early on Tuesday and take a break on Wednesday for Christmas Day. But light trading doesn't mean small moves in markets. "With the market's primary uptrends still intact, we are not giving up on the potential for a Santa Claus to come to Broad & Wall this year," Craig Johnson, chief market technician at Piper Sandler, said in a note. As investors celebrate the festivities — and the S&P's 25.25% year-to-date pop — they might find an extra present underneath the tree. — CNBC's Yun Li, MacKenzie Sigalos and Ari Levy contributed to this report. CNBC Daily Open will be on hiatus and return next year. Happy holidays!
- Previous:
- Next: lol646 redeem code
